Background: Molecular testing in advanced lung cancer is standard in guiding treatment selection. However, population-wide implementation of testing remains a challenge. We developed a knowledge translation intervention to improve understanding among diagnostic specialists about molecular testing and appropriate diagnostic sampling in lung cancer.
Introduction
Lung cancer remains the most commonly diagnosed cancer and leading cause of cancer-related mortality globally. 1 Scientific advances in the understanding of lung cancer biology have led to major progress in targeted treatment of adenocarcinoma and other therapeutic advances in lung cancer over the past decade. Among the most significant findings is the discovery of activating mutations in EGFR, 2 ALK receptor tyrosine kinase gene (ALK), and ROS1 rearrangements. 3, 4 In these molecular subgroups, first-line biomarker-directed therapy significantly improves response, quality of life, and progression-free survival (PFS) and is better tolerated than standard chemotherapy. [5] [6] [7] [8] [9] [10] More recently, the advances and encouraging results with immunotherapy resulted in the introduction of pembrolizumab as firstline treatment in patients with advanced NSCLC with high programmed death ligand 1 expression (tumor proportion score 50%) by immunohistochemistry. 11 Thus, molecular testing for these aberrations has become the standard of care, with most guidelines recommending that all patients with nonsquamous NSCLC have EGFR, ALK, ROS1, and programmed death ligand-1 testing performed on their diagnostic samples before initiation of first-line treatment, with a maximum turnaround time (TAT) of 10 working days. 10, [12] [13] [14] Despite this, many patients either do not have testing of their samples or do not receive the results in time for treatment decision making. Uptake of testing in a communitybased U.S. oncology network 15 increased from 2% to 32% of eligible advanced nonsquamous NSCLC cases from 2010 to 2011. In Canada, an estimated 37% of eligible patients had EGFR testing through a national program. 16 Up to 12% of samples received were insufficient for testing, and the TAT was 18 days. Review of a major Canadian cancer center's experience revealed that only 21% of patients with advanced nonsquamous lung cancer received EGFR/ALK testing results at the time of their initial oncology consultation. 17 Lack of available results at initial consultation led to significant delays in treatment decision making and treatment start, with 19% of patients with EGFR-mutant or ALK-rearranged lung cancer having to start chemotherapy before biomarker results were available.
Lack of reflex molecular testing and delayed TAT of results can prevent patients from receiving timely firstline targeted treatment that can improve response rates, prolong progression-free survival, and improve quality of life and (potentially) survival compared with empirical chemotherapy.
The reasons for the existing gap between successful molecular testing for all patients with advanced nonsquamous NSCLC and a reasonable TAT are multifactorial and include the lack of awareness of molecular testing guidelines among physicians that are involved in lung cancer diagnosis. A knowledge translation intervention was developed to improve understanding among Ontario diagnostic specialists about the importance of molecular testing and appropriate diagnostic sampling for molecular testing in lung cancer.
Key opinion and research leaders assisted in formulating key messages to promote lung cancer biomarker testing in Ontario (by consensus) and identification of barriers to molecular testing according to current guidelines. Educational programs for each specialty audience were subsequently developed, and participant knowledge specifically related to molecular testing was assessed before and after these programs were administered. We evaluated whether our knowledge translation intervention contributed to improved knowledge and awareness of molecular testing, as well as to changes in practice among Ontario diagnostic specialists.
Methods
The study conduct and data collection received ethics approval from the University Health Network Research Ethics Board.
Participants and Sampling
The Ontario specialists involved in the diagnosis and treatment of lung cancer included respirologists, pathologists, thoracic surgeons, radiologists, oncologists, pharmacists, and oncology nurses who had been identified and targeted through medical conferences, small group sessions, and specialty societies.
Intervention
A representative multidisciplinary panel was assembled to develop specialty-specific educational programs on the basis of level 1 evidence and published clinical guidelines. The intervention included presentation of current data and guidelines by a key opinion and research leader in the specialty of interest followed by multidisciplinary small group discussions led by members of the panel to identify both barriers to best testing practices and potential strategies to overcome the identified barriers at the local and provincial levels (see the Supplementary Data).
Data Collection
Anonymous questionnaires were distributed in meetings with participant permission, and self-reported data were collected over a 7-month period from April to October 2013. Preintervention and postintervention surveys included both open and closed questions regarding clinician perspectives and experiences with EGFR and ALK testing in patients with lung cancer. Survey questions addressed perceptions of patient eligibility, the timing and process for test initiation, and tissue sampling and handling requirements.
We evaluated molecular testing rates at baseline and at 3 months after completion of the educational interventions. Centralized tracking of EGFR testing was used to determine testing rates (by the Iressa Alliance, which was established and funded by Astra Zeneca Canada, Mississauga, Ontario, Canada). ALK testing in Canada is performed locally in many pathology laboratories by immunohistochemistry and is not yet tracked locally or provincially, thus precluding the assessment of changes in practice related to ALK testing rates.
Statistical Analysis
Comparisons were performed between preintervention and postintervention surveys by using chisquare tests for categorical variables, and associated p values were reported. The threshold for statistical significance was p less than 0.05. Comparison of testing rates in the 3-month periods before and after intervention was performed by using an independent samples t test. All analyses were conducted with SAS software (version 9.3, SAS Institute Inc., Cary NC).
Results
The conduct of this study was approved by the University Health Network Research Ethics Board. A total of 315 participants attended 10 knowledge translation intervention meetings that were held across Ontario.
Participant Characteristics
Preintervention surveys were answered by 255 out of the 315 participants (81%) and postintervention surveys were answered by 219 participants (70%). Participant characteristics are listed in Table 1 . Participants were most commonly pathologists, medical or radiation oncologists, and thoracic surgeons. Both groups (preintervention and postintervention) were balanced with respect to practice location (Ontario versus other), academic affiliation (w50% community-based hospitals), affiliation with a cancer facility (>90%), and experience with lung cancer diagnosis. The only significant difference between the groups was reduced reporting of specialty in the postintervention surveys compared with in the preintervention surveys (p ¼ 0.0024).
Baseline Knowledge and Practice
Current practice for lung cancer diagnosis and molecular testing by participants was evaluated in the preintervention survey only (Table 2 ). Surgical resection, fine-needle aspiration (FNA), and core biopsy were the most commonly used techniques for acquisition of tissue for diagnosis. Most clinicians (62%) reported acquiring more than half of all diagnostic samples in the absence of an on-site cytopathologist or pathologist for immediate specimen review. Only 15% of participants reported that they routinely order EGFR testing of 50% or more of the samples they obtain. Uncertainty over how and whom to test was the primary reason for not conducting molecular testing cited by 61% of responders. Of these, 29% were unfamiliar with test ordering procedures, 18% were unsure when to test, and 14% would not perform reflex testing if samples were not accompanied by a molecular testing order from a clinician. Once EGFR testing was initiated, participants estimated that results were available within a median of 14 days (range 2-30 days). More than half of respondents (54%) were completely unfamiliar with how to access EGFR or ALK testing for lung cancer samples. Only 21% were registered users of the online EGFR testing website, which was the primary platform for ordering EGFR testing in Ontario at the time. The sample size was too small to assess the impact of specialty on baseline knowledge.
Changes in Knowledge and Intention after Intervention
Knowledge of lung cancer diagnosis and molecular testing was assessed before and after the intervention. Before the intervention, 46% of respondents reported that they did not or rarely considered molecular testing when conducting biopsies for lung cancer compared with 35% after the intervention (Fig. 1) . The level of uncertainty regarding tissue sampling and processing to ensure successful molecular testing decreased significantly, with 30% of respondents unsure of appropriate tissue handling techniques before the intervention compared with 2% after the intervention (p < 0.001 [ Table 3 ]). Specialist knowledge regarding tissue handling techniques significantly increased after the intervention, with more respondents choosing to request cytology cell block preparation to enable testing (56% before versus 79% after intervention [p < 0.001]) and proper fixation methods (38% before versus 51% after intervention [p ¼ 0.007]). In all, 43% of respondents deferred the decision to initiate molecular testing to the patient's medical oncologist before the intervention; this rate decreased to 17% after the intervention (see Table 3 ). The proportion of specialists who would send samples for testing even if unsure that the sample was sufficient increased from 33% before the intervention to 69% afterward. After the intervention, participants became more knowledgeable about clinical features associated with ALK rearrangement and EGFR mutation; for example, the proportions of participants choosing younger age as a feature associated with ALK rearrangement before and after the intervention were 52% and 62%, respectively (p ¼ 0.08), and the proportions choosing Asian decent as a feature associated with EGFR mutations before and after the intervention were 63% and 82%, respectively (p < 0.001) (see Table 3 ). Still, the overall rate of incorrect responses regarding the clinical features after the intervention remained comparable to that before the intervention. Most importantly, participants understood the importance of members of the diagnostic team (such as surgeons, respirologists, interventional radiologists, or pathologists) initiating testing as soon as possible rather than delaying the decision by deferring to a medical oncologist, even if they were unsure of technical requirements (see Table 3 , Supplementary Table 1 , and Fig. 1 ).
Academic versus Community Centers
An exploratory analysis of responses by participants from academic versus community centers was performed to evaluate the possible impact of practice type on practice patterns and knowledge. Imbalances in subgroups were apparent, with greater representation of oncologists and thoracic surgeons from academic centers (p < 0.001). Results showed that compared with physicians from community centers, clinicians from academic centers diagnosed a larger number of lung cancer cases per physician (p < 0.001), were more knowledgeable regarding clinical features associated with EGFR mutations and ALK rearrangements, and were more aware of when to test for these aberrations. The knowledge levels regarding appropriate tissue sampling and processing were comparable. Additional exploratory analysis was also performed by analyzing participant responses according to lung cancer cases diagnosed or treated per month. There were no significant differences in knowledge or reported testing practice according to lung cancer case load.
Identifying Barriers and Solutions
The main barriers to best testing practices that were identified related to (1) optimal tissue sampling (e.g., how to choose between FNA or core biopsy), (2) the lack of cytopathologists at the time of sample collection, and (3) procedures to ensure that molecular testing was initiated. Concerns reported from participants included estimated costs and the ability of the health care system to manage the rising demands of molecular testing. Strategies identified to overcome these barriers included (1) use of both FNA and core biopsy for diagnosis of lung cancer as a routine and (2) improvement of team communication, including prompt reporting from pathologists in cases of inadequate tissue sampling. Finally, the need for local protocols specifying the timing and manner of sampling and processing requirements was highlighted in several discussions, as was the need for reflex testing upon lung cancer diagnosis.
Translation of Knowledge to Practice
Changes in real-world practice patterns were assessed by comparing preintervention and postintervention testing rates. In the 3 months before the intervention, an estimated 157 samples per month were sent for molecular testing. In the 3 months after the intervention, and an estimated 247 samples were sent for testing. Assuming similar incidences of lung cancer diagnosis in the time frames evaluated, this represents a 57% increase in samples sent for EGFR testing across Ontario.
Discussion
The need for knowledge translation initiatives to improve molecular testing in lung cancer has been indicated by several groups across the globe, [16] [17] [18] [19] and to our knowledge, this is the first such intervention.
Our baseline evaluation suggests uncertainty as the main reason for not sending samples for molecular testing by specialists in Ontario. More than 50% of participants were unfamiliar with how to access EGFR and ALK testing, 46% reported not or rarely considering testing when conducting biopsies, 30% were unsure which sampling technique and tissue handling methods were appropriate, and 42% preferred deferring this decision to the medical oncologist. Although specialists working in academic centers were more knowledgeable about clinical features associated with EGFR and ALK genetic aberrations, they were as unfamiliar with tissue handling techniques as specialists from community centers were. This uncertainty could explain the lower than expected testing rates found in Canada, 16 as well as in our estimation of the Ontario lung cancer population. Similar findings were seen in a 2011New Zealand study evaluating physicians' awareness of EGFR testing after the introduction of testing. Of the 61 clinicians from specialties involved in lung cancer management, fewer than 30% had actual experience ordering EGFR testing. On the basis of their experience, participants estimated that less than 10% of all patients in New Zealand with underwent EGFR testing in 2011, but an evaluation of actual testing rates was not reported. 19 Ongoing knowledge translation of progress in lung cancer diagnosis and therapy to specialists involved in diagnosis is essential.
The main limitation of this study is that a preintervention versus postintervention survey comparison at the individual participant level was not available because the surveys were anonymous. Survey participation was voluntary and not all intervention participants completed both surveys, although the groups were well balanced with regard to most parameters. In addition, although specific specialties were targeted, we were fortunate to have a broader group of participants, including specialized oncology nurses and pathology technicians. We were unable to perform subgroup analyses by specialty because of small numbers.
Translation of Knowledge to Practice
We calculated annual testing rates for EGFR in Ontario on the basis of the number of tests ordered through the online ordering system. With the assumption of similar incidences of lung cancer diagnosis in the time frames evaluated, our study reports a 57% increase in samples sent for EGFR testing across Ontario in the months after the intervention. The ability to extrapolate the overall effect of the intervention to actual practice patterns is limited, with other potentially contributing 
Barriers and Solutions
The barriers to optimizing molecular testing add to the complexity of diagnostic and treatment algorithms in NSCLC and affect the overall time from diagnosis to treatment initiation, thus impairing patient access to treatment and outcomes. Patients with results available at the time of the initial oncology consultation benefit from earlier initiation of systemic therapy, yet they represent a minority of cases. 17 To overcome these barriers, changes are required at individual, institutional, and provincial levels. Institutional policy change requires provincial endorsement and funding. Potential solutions include reflex testing, (ie, incorporating testing into the diagnostic algorithm funded by the system), funding for rapid on-site evaluation of diagnostic samples by cytopathologists, and use of testing rates as a quality indicator in cancer care. These can help improve TAT and testing success rates. Similarly, approaching and educating individuals involved in lung cancer diagnosis and molecular testing as interventional radiologists, respirologists, pathology technicians, and pathologists, as described in this study, can result in a significant increase in testing rates and test success. Knowledge transfer and education about advances in lung cancer diagnosis and therapy must occur not only through training programs but also by targeting of practicing clinicians. These should include in person and web-based education, and should be incorporated into guidelines regarding best practices for diagnosis. 20 
Conclusions
To our knowledge, this is one of the first reported studies to develop a knowledge translation intervention for optimizing molecular testing in advanced NSCLC. Significant knowledge gaps exist in optimal molecular testing for NSCLC among specialists who diagnose this disease in Ontario. Our knowledge translation intervention improved knowledge and awareness regarding molecular testing, as well as its importance in lung cancer and relevance to improving patient outcomes. The intervention correlated with a significant increase in specialist understanding of the importance of molecular testing and successful techniques required for molecular diagnosis. It also correlated with increased molecular testing rates in Ontario over the period of the intervention. Improved communication among specialists involved in lung cancer diagnosis and patient care and the establishment of local molecular testing protocols to increase testing success rates are essential.
